27 June 2016
Type 1 diabetes is an autoimmune disease that strikes suddenly, usually in children and young adults, and has no known cure. Over 120,000 Australian children and adults have type 1 diabetes, with six new cases diagnosed every day.
Half of those diagnosed are under the age of 18. The causes of type 1 diabetes are not fully understood but researchers have identified a variety of genetic and environmental triggers. While the disease can be managed through blood monitoring, insulin therapy, diet and exercise, the only hope for a cure lies in ongoing medical research.
JDRF is a global organisation which aims to cure, prevent and treat type 1 diabetes and its complications. It works with academic institutions, policymakers, and corporate and industry partners to develop and deliver therapies to people living with the disease and to restore the body’s normal ability to produce insulin after the disease strikes.
In 2008, JDRF Australia and the Macquarie Group Foundation created the Global Diabetes Research Innovation Partnership to increase the volume and impact of type 1 diabetes research in Australia and around the world. This support has meant JDRF can help shape the international research agenda and influence decisions across the medical health spectrum.
CEO, JDRF Australia
In March 2016, Macquarie approved a further A$540,000 to JDRF, as part of a new three-year partnership. JDRF also has many supporters among Macquarie’s global staff, some of whom have been personally touched by the disease. They have participated in JDRF fundraising initiatives for many years, raising more than A$1 million, together with Macquarie Group Foundation matching.
Phase 1 of the partnership, which focused on Australian research development, included:
Phase 2, which extended the partnership globally, included:
JDRF funded research projects have included:
Source: JDRF Australia, March 2016